Merck Manual

Please confirm that you are a health care professional

honeypot link

Acute Interstitial Pneumonia

(Accelerated Interstitial Pneumonia; Hamman-Rich Syndrome)


Joyce Lee

, MD, MAS, University of Colorado School of Medicine

Last full review/revision Jun 2021| Content last modified Jun 2021
Click here for Patient Education

AIP is defined histologically by organizing diffuse alveolar damage, a nonspecific pattern that occurs in other causes of lung injury unrelated to idiopathic interstitial pneumonia. The hallmark of organizing diffuse alveolar damage is diffuse, marked alveolar septal edema with inflammatory cell infiltration, fibroblast proliferation, occasional hyaline membranes, and thickening of the alveolar walls. Septa are lined with atypical, hyperplastic type II pneumocytes, and airspaces are collapsed. Thrombi develop in small arteries but are nonspecific.

Symptoms of acute interstitial pneumonia consist of the abrupt onset of fever, cough, and shortness of breath, which in most patients increase in severity over 7 to 14 days, progressing to respiratory failure Acute Hypoxemic Respiratory Failure (AHRF, ARDS) Acute hypoxemic respiratory failure is defined as severe hypoxemia (PaO2 (See also Overview of Mechanical Ventilation.) Airspace filling in acute hypoxemic respiratory failure (AHRF) may result... read more Acute Hypoxemic Respiratory Failure (AHRF, ARDS) .

Diagnosis of Acute Interstitial Pneumonia

  • High resolution CT (HRCT)

  • Sometimes lung biopsy

High-resolution CT (HRCT) supports the diagnosis of AIP, but definitive diagnosis usually requires biopsy. HRCT shows bilateral patchy symmetric areas of ground-glass attenuation and sometimes bilateral areas of airspace consolidation in a predominantly subpleural distribution. Mild honeycombing, usually affecting < 10% of the lung, may be present. Routine laboratory tests are nonspecific and generally not helpful.

Surgical lung biopsy showing diffuse alveolar damage in the absence of known causes of ARDS and diffuse alveolar damage (eg, sepsis, drugs, toxins, radiation, viral infection) confirms a diagnosis of AIP. Acute exacerbation of underlying lung disease (in particular acute exacerbation of idiopathic pulmonary fibrosis Idiopathic Pulmonary Fibrosis Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial pneumonia, causes progressive pulmonary fibrosis. Symptoms and signs develop over months to years and include... read more Idiopathic Pulmonary Fibrosis ) must be considered and may explain some cases previously characterized as AIP. Biopsy is often required to distinguish AIP from diffuse alveolar hemorrhage Diffuse Alveolar Hemorrhage Diffuse alveolar hemorrhage is persistent or recurrent pulmonary hemorrhage. There are numerous causes, but autoimmune disorders are most common. Most patients present with dyspnea, cough, hemoptysis... read more Diffuse Alveolar Hemorrhage , acute eosinophilic pneumonia Acute Eosinophilic Pneumonia Acute eosinophilic pneumonia (AEP) is a disorder of unknown etiology characterized by rapid eosinophilic infiltration of the lung interstitium. (See also Overview of Eosinophilic Pulmonary Diseases... read more , and cryptogenic organizing pneumonia Cryptogenic Organizing Pneumonia Cryptogenic organizing pneumonia is an idiopathic condition in which granulation tissue obstructs alveolar ducts and alveolar spaces with chronic inflammation occurring in adjacent alveoli.... read more Cryptogenic Organizing Pneumonia . However, the risks and benefits of surgical lung biopsy must be carefully considered.

Treatment of Acute Interstitial Pneumonia

  • Supportive care

Treatment of acute interstitial pneumonia is supportive and usually requires mechanical ventilation, often using the same methods as used for ARDS (including low tidal volume ventilation Treatment Acute hypoxemic respiratory failure is defined as severe hypoxemia (PaO2 (See also Overview of Mechanical Ventilation.) Airspace filling in acute hypoxemic respiratory failure (AHRF) may result... read more Treatment ). Corticosteroid therapy is generally used, but efficacy has not been established.

Mortality is > 60%; most patients die within 6 months of presentation, and death is usually due to respiratory failure. Patients who survive the initial acute episode may recover complete pulmonary function, although the disease may recur.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
quiz link

Test your knowledge

Take a Quiz!